Innovent Biologics (HKG:1801) and Hutchmed (China) (HKG:0013) obtained approval for a new drug application for the combination of TYVYT and ELUNATE from China's National Medical Products Administration, according to a Thursday filing with the Hong Kong bourse.
The combination is intended to treat patients with locally advanced or metastatic renal cell carcinoma.
Hutchmed co-developed ELUNATE with Eli Lilly and Company, while TYVYT was co-developed by Innovent Biologics and Eli Lilly.